Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now indicates that recruitment has ended for this study. It also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and includes a minor label formatting change for Intervention/Treatment.SummaryDifference0.4%

- Check20 days agoChange DetectedThe page revision tag was updated from v3.5.4 to v3.5.5, indicating a new deployment of the page.SummaryDifference0.0%

- Check41 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer version of the page has been published.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance or release update rather than a change to the study information.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded Small cell lung carcinoma as a condition tag and introduced a Resources section linking Genetic and Rare Diseases Information Center.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.